These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37409798)

  • 21. [Determination of the synthesis of poliovirus antigens with the use of gamma-globulin labled with I-131].
    Peterson OP; Mel'nikova LA; Kozlova IA
    Vopr Virusol; 1965; 10(3):287-9. PubMed ID: 4161096
    [No Abstract]   [Full Text] [Related]  

  • 22. Vaccine-Derived Polioviruses and Children with Primary Immunodeficiency, Iran, 1995-2014.
    Shaghaghi M; Shahmahmoodi S; Abolhassani H; Soleyman-Jahi S; Parvaneh L; Mahmoudi S; Chavoshzadeh Z; Yazdani R; Zahraei SM; Ebrahimi M; Eslamian MH; Tabatabaie H; Yousefi M; Kandelousi YM; Oujaghlou A; Rezaei N; Aghamohammadi A
    Emerg Infect Dis; 2016 Oct; 22(10):1712-9. PubMed ID: 27648512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data.
    Shaghaghi M; Soleyman-Jahi S; Abolhassani H; Yazdani R; Azizi G; Rezaei N; Barbouche MR; McKinlay MA; Aghamohammadi A
    Vaccine; 2018 Mar; 36(13):1711-1719. PubMed ID: 29478755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Underperformed and Underreported Testing for Persistent Oropharyngeal Poliovirus Infections in Primary Immune Deficient Patients-Risk for Reemergence of Polioviruses.
    Shulman LM; Weil M; Somech R; Stauber T; Indenbaum V; Rahav G; Mendelson E; Sofer D
    J Pediatric Infect Dis Soc; 2021 Apr; 10(3):326-333. PubMed ID: 32538431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine-derived poliomyelitis 12 years after infection in Minnesota.
    DeVries AS; Harper J; Murray A; Lexau C; Bahta L; Christensen J; Cebelinski E; Fuller S; Kline S; Wallace GS; Shaw JH; Burns CC; Lynfield R
    N Engl J Med; 2011 Jun; 364(24):2316-23. PubMed ID: 21675890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6P disease.
    Fultz PN; Stallworth J; Porter D; Novak M; Anderson MJ; Morrow CD
    Virology; 2003 Oct; 315(2):425-37. PubMed ID: 14585346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poliovirus excretion following vaccination with live poliovirus vaccine in patients with primary immunodeficiency disorders: clinicians' perspectives in the endgame plan for polio eradication.
    Galal NM; Meshaal S; ElHawary R; Nasr E; Bassiouni L; Ashghar H; Farag NH; Mach O; Burns C; Iber J; Chen Q; ElMarsafy A
    BMC Res Notes; 2018 Oct; 11(1):717. PubMed ID: 30305145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. REACTIVATION BY PHYSICAL MEANS OF ANTIBODY-NEUTRALIZED POLIOVIRUS.
    KELLER R
    J Immunol; 1965 Jan; 94():143-9. PubMed ID: 14253512
    [No Abstract]   [Full Text] [Related]  

  • 29. Absence of wild poliovirus circulation among healthy children in a rural area with high oral poliovirus vaccination coverage.
    Deshpande JM; Rao VK; Karnataki MV; Nadkarni SS; Saxena VK; Karambelkar RR; Ramdasi SG; Patil KS; Rodrigues JJ
    Indian J Med Res; 1996 Jun; 103():289-93. PubMed ID: 8707367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CHARACTERIZATION OF VIRUS NEUTRALIZING ANTIBODIES IN HUMAN SERUM AND NASAL SECRETIONS.
    BELLANTI JA; ARTENSTEIN MS; BUESCHER EL
    J Immunol; 1965 Mar; 94():344-51. PubMed ID: 14279784
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical trial of sulfonated immunoglobulin preparation for intravenous administration. I. Replacement therapy for primary immunodeficiency syndromes.
    Kobayashi N; Gohya N; Matsumoto S
    Eur J Pediatr; 1981 May; 136(2):159-65. PubMed ID: 6164554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Control of a type 1 poliomyelitis epidemic in British Guiana, 1962-63, with trivalent oral poliovirus vaccine. 2. Virological aspects.
    Feldman RA; Mootoo CL; Spence L; Gelfand HM
    Bull World Health Organ; 1965; 33(1):13-9. PubMed ID: 4284022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poliovirus surveillance in patients with primary immunodeficiencies, India.
    Mohanty MC; Mohammad A; Verma H; Kumar A; Madkaikar MR; Desai M; Varose SY; Sawant U; Yadav RM; Taur P; Kathuria R; Tatkare M; Murhekar M; Haldar P; Abraham P
    Bull World Health Organ; 2023 May; 101(5):346-354. PubMed ID: 37131936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015.
    Diop OM; Burns CC; Sutter RW; Wassilak SG; Kew OM;
    MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(23):640-6. PubMed ID: 26086635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication.
    Aghamohammadi A; Abolhassani H; Kutukculer N; Wassilak SG; Pallansch MA; Kluglein S; Quinn J; Sutter RW; Wang X; Sanal O; Latysheva T; Ikinciogullari A; Bernatowska E; Tuzankina IA; Costa-Carvalho BT; Franco JL; Somech R; Karakoc-Aydiner E; Singh S; Bezrodnik L; Espinosa-Rosales FJ; Shcherbina A; Lau YL; Nonoyama S; Modell F; Modell V; ; Barbouche MR; McKinlay MA
    Front Immunol; 2017; 8():685. PubMed ID: 28952612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MOLECULAR PROPERTIES OF POLIOVIRUS NEUTRALIZING ANTIBODIES IN HUMAN COLOSTRUM AND MILK.
    GIOVANARDI A; PERNIS B; ALBANO A; AMANTE L; DEDONATO S
    Arch Gesamte Virusforsch; 1965; 15():356-65. PubMed ID: 14292781
    [No Abstract]   [Full Text] [Related]  

  • 37. [Neutralizing effects of German gamma globulin preparations on poliomyelitis virus type I (Brunhilde) and type III (Leon)].
    HAAS R; DOSTAL V
    Dtsch Med Wochenschr; 1954 Jul; 79(27-28):1071-2. PubMed ID: 13182905
    [No Abstract]   [Full Text] [Related]  

  • 38. Neutralization of three immunological types of poliomyelitis virus by human gamma globulin.
    BODIAN D
    Proc Soc Exp Biol Med; 1949 Oct; 72(1):259-61. PubMed ID: 15391731
    [No Abstract]   [Full Text] [Related]  

  • 39. THE FORMATION AND PROPERTIES OF POLIOVIRUS NEUTRALIZING ANTIBODY. 5. CHANGES IN THE QUALITY OF 19S AND 7S RABBIT ANTIBODIES FOLLOWING IMMUNIZATION.
    SVEHAG SE
    Acta Pathol Microbiol Scand; 1965; 64():103-18. PubMed ID: 14320670
    [No Abstract]   [Full Text] [Related]  

  • 40. Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative.
    Dunn G; Klapsa D; Wilton T; Stone L; Minor PD; Martin J
    PLoS Pathog; 2015 Aug; 11(8):e1005114. PubMed ID: 26313548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.